Business & Industry

The NHS has partnered with leading pharmaceutical companies to establish a £10 million Respiratory Transformation Partnership, a coordinated programme designed to improve care delivery for asthma and chronic obstructive pulmonary disease (COPD) patients across England while easing systemic pressure...

Key Takeaways: The multi-vendor model in biopharma CMC creates communication risk, timeline gaps, and regulatory complexity Integrated CDMO partnerships consolidate development and manufacturing under a single organization with end-to-end knowledge of the process Single-partner models improve technology transfer efficiency...

SGD Pharma has entered into a Franco-American OEM collaboration with Prince Sterilization Services, LLC to validate Ready-to-Use (RTU) Type I glass primary packaging solutions for the North American market. As the first outcome of this partnership, the companies have...

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.